19:30 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

HPV testing improves cervical intraepithelial neoplasia detection vs. liquid-based cytology

The Canadian Institutes of Health Research (CIHR) published data from a study in the Journal of the American Medical Association suggesting that primary HPV-based screening detects cervical intraepithelial neoplasia (CIN) earlier and more accurately than...
05:50 , Jun 2, 2018 |  BioCentury  |  Product Development

Breaking from the herd

Behind the block of clinical studies on PD-1 and PD-L1 inhibitors, researchers are casting aside their herd mentality with a wide net of strategies to solve some of the most pressing problems in oncology, such...
19:52 , Feb 23, 2018 |  BioCentury  |  Emerging Company Profile

Cutting viruses

Armed with a suite of CRISPR nucleases and multiple guide RNAs, Excision BioTherapeutics Inc. is using gene editing to cut out integrated latent viruses from host genomes. The newco is starting with HIV, but has...
20:19 , Jun 9, 2017 |  BC Week In Review  |  Clinical News

Inovio resumes VGX-3100 HPV cancer program

Inovio Pharmaceuticals Inc. (NASDAQ:INO) said FDA lifted a clinical hold on its Phase III program of VGX-3100 to treat cervical dysplasia caused by HPV. The company plans to immediately begin a pair of Phase III...
22:46 , Jun 8, 2017 |  BC Extra  |  Clinical News

Inovio resumes VGX-3100 HPV cancer program

Inovio Pharmaceuticals Inc. (NASDAQ:INO) gained $0.80 (11%) to $8.19 on Thursday after the company said FDA lifted a clinical hold on its Phase III program of VGX-3100 to treat cervical dysplasia caused by HPV. The...
15:02 , Jun 2, 2017 |  BC Week In Review  |  Clinical News

Immunovaccine begins Phase Ib/II of HPV-related cancer vaccine DPX-E7

In April, Immunovaccine Inc. (TSX:IMV; OTCQX:IMMVF) said that the Dana-Farber Cancer Institute (Boston, Mass.) began a Phase Ib/II trial of the biotech’s DPX-E7 plus low-dose cyclophosphamide in 44 patients who are HLA-A*02-positive with incurable HPV...
19:56 , May 24, 2017 |  BC Innovations  |  Translation in Brief

Unusual suspects

While viral proteins have been considered prime targets for immunotherapy in cancers triggered by viral infections, an NCI study indicates mutated host antigens could be equally or more immunogenic. The study, published in Science last month,...
00:28 , May 2, 2017 |  BC Week In Review  |  Clinical News

Inovio starts Ph II of HPV vaccine VGX-3100

Inovio Pharmaceuticals Inc. (NASDAQ:INO) began a Phase II trial to evaluate intramuscular VGX-3100 in 36 patients with vulvar intraepithelial neoplasia (VIN). The open-label trial is evaluating the primary endpoint of clearance of high-grade lesions and...
23:11 , Feb 24, 2017 |  BioCentury  |  Product Development

Dendritic cell control

Denceptor Therapeutics Ltd. is developing a technology for inducing antigen-specific T cell responses that the company believes will be more efficacious than other dendritic cell-targeted approaches for cancer while avoiding the safety issues raised by...
20:28 , Feb 16, 2017 |  BC Week In Review  |  Company News

Inovio, ApolloBio deal

Inovio granted ApolloBio exclusive rights to develop and commercialize VGX-3100 in Taiwan and China, including Hong Kong and Macau, to treat or prevent pre-cancerous infections and dysplasias tied to HPV. Inovio will receive $3 million...